WP
HARP

Woodline Partners’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Woodline Partners’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,894
Closed -$914K – 202
2020
Q1 		$914K Buy
+7,894
New +$1.11M 0.07% 127

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners's HARP Position: Q2 2020 in Review

Woodline Partners sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2020, closing a stake of 7,894 shares — an estimated $914K sold.

Woodline Partners first reported a position in HARP in Q1 2020 and held it in 1 quarter. The position peaked at $914K in Q1 2020. 69 funds tracked by Wall St. Rank hold HARP as of Q2 2020.

  • Woodline Partners reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Woodline Partners sold 7,894 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $914K.
  • Woodline Partners first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Woodline Partners's Harpoon Therapeutics, Inc. Common Stock position peaked at $914K in Q1 2020.
  • 69 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Woodline Partners's 13F filing for Q2 2020, filed 14 Aug 2020.